MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 13, 2008; DOI: 10.1124/mol.108.049056


0026-895X/08/7405-1443-1452$20.00
Mol Pharmacol 74:1443-1452, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.108.049056v1
74/5/1443    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perrin, M. J.
Right arrow Articles by Vandenberg, J. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perrin, M. J.
Right arrow Articles by Vandenberg, J. I.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Medicines

Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-à-go-go-Related Gene ChannelsFormula

Mark J. Perrin, Philip W. Kuchel, Terence J. Campbell, and Jamie I. Vandenberg

Mark Cowley Lidwill Research Program in Electrophysiology and Biophysics, Victor Chang Cardiac Research Institute, New South Wales, Australia (M.J.P., T.J.C., J.I.V.); St. Vincent's Clinical School, University of New South Wales, New South Wales, Australia (M.J.P., T.J.C., J.I.V.); and School of Molecular and Microbial Biosciences, University of Sydney, New South Wales, Australia (P.W.K., J.I.V.)

Drug block of the human ether-à-go-go-related gene K+ channel (hERG) is the most common cause of acquired long QT syndrome, a disorder of cardiac repolarization that may result in ventricular tachycardia and sudden cardiac death. We investigated the open versus inactivated state dependence of drug block by using hERG mutants N588K and N588E, which shift the voltage dependence of inactivation compared with wild-type but in which the mutated residue is remote from the drug-binding pocket in the channel pore. Four high-affinity drugs (cisapride, dofetilide, terfenadine, and astemizole) demonstrated lower affinity for the inactivation-deficient N588K mutant hERG channel compared with N588E and wild-type hERG. Three of four low-affinity drugs (erythromycin, perhexiline, and quinidine) demonstrated no preference for N588E over N588K channels, whereas dl-sotalol was an example of a low-affinity state-dependent blocker. All five state-dependent blockers showed an even lower affinity for S620T mutant hERG (no inactivation) compared with N588K mutant hERG (greatly reduced inactivation). Computer modeling indicates that the reduced affinity for S620T compared with N588K and wild-type channels can be explained by the relative kinetics of drug block and unblock compared with the kinetics of inactivation and recovery from inactivation. We were also able to calculate, for the first time, the relative affinities for the inactivated versus the open state, which for the drugs tested here ranged from 4- to 70-fold. Our results show that preferential binding to the inactivated state is necessary but not sufficient for high-affinity binding to hERG channels.


Received for publication May 21, 2008.

Accepted for publication August 13, 2008.

Address correspondence to: Dr. Jamie I. Vandenberg, Victor Chang Cardiac Research Institute, 384 Victoria Street, Darlinghurst, NSW 2010, Australia. E-mail: j.vandenberg{at}victorchang.edu.au




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
P. Ju, G. Pages, R. P. Riek, P.-c. Chen, A. M. Torres, P. S. Bansal, S. Kuyucak, P. W. Kuchel, and J. I. Vandenberg
The Pore Domain Outer Helix Contributes to Both Activation and Inactivation of the hERG K+ Channel
J. Biol. Chem., January 9, 2009; 284(2): 1000 - 1008.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics